CD74: an emerging opportunity as a therapeutic target in cancer and autoimmune disease.
about
CD74 in Kidney DiseaseMIF and CXCL12 in Cardiovascular Diseases: Functional Differences and SimilaritiesMacrophage migration inhibitory factor: a potential driver and biomarker for head and neck squamous cell carcinomaA multi-targeted approach to suppress tumor-promoting inflammationTranscriptome analysis of epigenetically modulated genome indicates signature genes in manifestation of type 1 diabetes and its prevention in NOD miceDeletion of CD74, a putative MIF receptor, in mice enhances osteoclastogenesis and decreases bone massMacrophage migration inhibitory factor-CXCR4 is the dominant chemotactic axis in human mesenchymal stem cell recruitment to tumors.Hippocampal gene expression meta-analysis identifies aging and age-associated spatial learning impairment (ASLI) genes and pathways.Phase I study of the anti-CD74 monoclonal antibody milatuzumab (hLL1) in patients with previously treated B-cell lymphomasProtective role of macrophage migration inhibitory factor in nonalcoholic steatohepatitis.Target proteomic profiling of frozen pancreatic CD24+ adenocarcinoma tissues by immuno-laser capture microdissection and nano-LC-MS/MS.Stromal-dependent tumor promotion by MIF family members.Activated RET and ROS: two new driver mutations in lung adenocarcinoma.Macrophage migration inhibitory factor - a therapeutic target in gallbladder cancer.CD74 and macrophage migration inhibitory factor as therapeutic targets in gastric cancer.MIF and autophagy: a novel link beyond "eating"Proton irradiation impacts age-driven modulations of cancer progression influenced by immune system transcriptome modifications from splenic tissuecDNA phage display for the discovery of theranostic autoantibodies in rheumatoid arthritis.Network analysis of gene lists for finding reproducible prognostic breast cancer gene signatures.Effect of myeloid differentiation primary response gene 88 on expression profiles of genes during the development and progression of Helicobacter-induced gastric cancerLoss of CD73-mediated actin polymerization promotes endometrial tumor progression.Urinary proteomic shotgun approach for identification of potential acute rejection biomarkers in renal transplant recipients.Predictors of survival in never-smokers with non-small cell lung cancer: a large-scale, two-phase genetic studyArrest Functions of the MIF Ligand/Receptor Axes in Atherogenesis.Inflammatory Marker Testing Identifies CD74 Expression in Melanoma Tumor Cells, and Its Expression Associates with Favorable Survival for Stage III Melanoma.Relationship between elevated soluble CD74 and severity of experimental and clinical ALI/ARDSA novel regulatory pathway for autoimmune disease: binding of partial MHC class II constructs to monocytes reduces CD74 expression and induces both specific and bystander T-cell toleranceMacrophage migration inhibitory factor receptor CD74 mediates alphavirus-induced arthritis and myositis in murine models of alphavirus infection.Molecular basis for impaired collateral artery growth in the spontaneously hypertensive rat: insight from microarray analysisThe role of macrophage migration inhibitory factor in autoimmune liver disease.Prognostic significance of CD44 in human colon cancer and gastric cancer: Evidence from bioinformatic analyses.ROS1 as a 'druggable' receptor tyrosine kinase: lessons learned from inhibiting the ALK pathway.Chronic lymphocytic leukaemia--the role of the microenvironment pathogenesis and therapy.Innate immunity and cell death in alcoholic liver disease: role of cytochrome P4502E1.CCL2 is transcriptionally controlled by the lysosomal protease cathepsin S in a CD74-dependent manner.The human-specific invariant chain isoform Iip35 modulates Iip33 trafficking and function.The biological function and significance of CD74 in immune diseases.Porcine CD74 is involved in the inflammatory response activated by nuclear factor kappa B during porcine circovirus type 2 (PCV-2) infection.CD74 and intratumoral immune response in breast cancer.Immunotherapy for B-Cell Neoplasms using T Cells expressing Chimeric Antigen Receptors: From antigen choice to clinical implementation.
P2860
Q26781254-64BEE050-B275-4657-A762-999CED4EAFCDQ26800135-E6C21D50-F7DC-433E-9B6C-D0DA4877FB6CQ28068581-AA50AC1C-7E1A-42C3-A9F7-19212557A4B5Q28393278-471776ED-1BBC-4246-9BD8-A88564175ED0Q28485365-63DD24E6-B68E-43AE-A046-095C8CBF7034Q30534461-A68FFDE1-5BAA-4318-A6D0-6E0FF04FBE58Q30632123-B6F31746-D588-4EAC-9F4C-2D90AA32F5A0Q31123604-7A14CBC0-577C-4BD0-8F77-06A0456BF161Q33421020-1519E499-738F-43EB-B582-D9E5DC37B7FEQ34512910-C42B585C-1BEF-42C1-B9EF-82A913C4941AQ34725880-62D1B671-1BED-4802-9F8F-5FCB7884DC7FQ34944820-6704E2FF-688C-46D4-84FD-301FCE27E3DBQ35206630-8C5EFA29-2922-4B55-A59B-0856A34723CFQ35830961-27FA613B-4675-471E-A924-708A8B6F85EFQ35958283-A151624B-8201-4C68-8739-961AE62C0E5AQ36009197-9E5CF8EB-33A7-4191-82F4-484B2DC20061Q36078666-7FC314AD-06D1-49F4-9DFA-F088B3D73CD0Q36098311-245F5EF2-6C36-4EA8-ADB3-A6CC4F853D02Q36254419-EF33C370-4DC8-4F7C-A8A1-7EBA20FB3DB9Q36281632-0A15A1E6-F17C-4A3C-B67B-E70B8337C770Q36430733-0B626B9D-04D2-49BA-98A0-B1E0DBDA0780Q36578296-35615167-7973-49FC-9367-C87EB126B19AQ36808416-2F5A2656-2A23-4359-A4B7-862E354D98CBQ36848077-3CA2B37C-232E-4DAA-9856-F87D1692592FQ37014210-A9FFC296-9762-4FF0-8413-353A42FF35D4Q37117393-28583DC0-13E4-4A99-A479-26DD89C6038CQ37212157-00B485D8-8F53-407F-9304-A459A1228F91Q37229642-51EEE49F-57DD-48FA-82E4-D292D8E53D6CQ37319355-D61B5E80-E94D-4033-8C85-9D77F0AB8369Q37423459-0E806D2C-EFDD-4845-B2ED-9FF59F4FE2BEQ37564476-9BC651D0-2740-4F7B-B22B-7C2DB5402203Q38002468-83C8F556-B19C-47A3-9E99-29B3C0EB6866Q38101683-864B3006-3C6D-40A4-9533-856D5FEED6A1Q38245446-AEB321A0-A522-4DF8-8439-4D644B0E0EE8Q38286205-C87385D1-2308-4CB9-AAD2-F49575CFDB6FQ38979171-7B188D31-D213-49B5-9CB5-467909743215Q38983516-EDACF015-0E45-44C5-901F-053A763BA92BQ39143909-62A75FFE-49B7-40D2-BB47-A04D3CDA296BQ41808474-44B587A7-27D7-4A2C-B3B9-4EF599AD7CA7Q42427577-0CE0C9A1-C48E-4A04-B8C8-21AEE5EB6E38
P2860
CD74: an emerging opportunity as a therapeutic target in cancer and autoimmune disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 January 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
CD74: an emerging opportunity as a therapeutic target in cancer and autoimmune disease.
@en
CD74: an emerging opportunity as a therapeutic target in cancer and autoimmune disease.
@nl
type
label
CD74: an emerging opportunity as a therapeutic target in cancer and autoimmune disease.
@en
CD74: an emerging opportunity as a therapeutic target in cancer and autoimmune disease.
@nl
prefLabel
CD74: an emerging opportunity as a therapeutic target in cancer and autoimmune disease.
@en
CD74: an emerging opportunity as a therapeutic target in cancer and autoimmune disease.
@nl
P2860
P1476
CD74: an emerging opportunity as a therapeutic target in cancer and autoimmune disease.
@en
P2093
Federica Borghese
Felix I L Clanchy
P2860
P304
P356
10.1517/14728222.2011.550879
P407
P577
2011-01-06T00:00:00Z